Related transcription enhancer factor-1 (RTEF-1) has previously been demonstrated to play an important role in both endothelial cells and cardiomyocytes. However, the function of RTEF-1 in the communication between these two adjacent cell types has not been elucidated.
Introduction
The anatomically close relationship between capillaries and myocardium allows not only for physiological transportation but also for cell-to-cell signalling between the capillary endothelial cells and cardiomyocytes. 1 Recently, it has been argued that signalling between myocardium and vasculature promotes reciprocal growth in a paracrine fashion. 2 In addition, physiological or compensatory cardiac hypertrophy is accompanied by normal or increased numbers of myocardial capillaries, suggesting that angiogenesis occurring within the heart may promote hypertrophy of adjacent cardiomyocytes. 3 Blocked or disrupted angiogenesis leads to pathological hypertrophy or heart failure, 4 a finding that is consistent with the fact that dilated cardiomyopathy is associated with an irregular capillary pattern and a reduction in overall capillary density. 5 Related transcription enhancer factor-1 (RTEF-1) has been reported to regulate cardiac hypertrophy 6 and angiogenesis. 7 As a member of the transcriptional enhancer factor (TEF) family, RTEF-1 is primarily expressed in skeletal muscle, 8 smooth muscle, 9 and cardiac muscle. 8 RTEF-1 regulates gene expression through binding to the muscle-specific cytidine-adenosine-thymidine (MCAT) element in the promoters of muscle-specific genes. 8 RTEF-1 can mediate the reactivation of the a 1 -adrenergic response to induce hypertrophy and reactivate cardiac and skeletal genes, such as b-myosin heavy chain and skeletal a-actin. 6 Transgenic mice that over-express RTEF-1 specifically in cardiomyocytes develop progressive atrial arrhythmias. 10 Recently, we demonstrated that RTEF-1 increases promoter activity and expression of vascular endothelial growth factor (VEGF)-A in both normoxic and hypoxic conditions. 7 Sequential deletion and site-directed mutational analyses of the VEGF-A promoter demonstrated that a GC-rich region containing four special protein 1 (Sp1) response elements was essential for regulation of VEGF-A by RTEF-1. Interestingly, this region does not contain MCAT elements. 7, 11 There are five members of the VEGF family [VEGF-A, -B, -C, -D, and placental growth factor (PIGF)], which are key regulators of angiogenesis, vasculogenesis, and lymphoangiogenesis. 12 VEGF-B is widely expressed in various tissues and is particularly abundant in heart. 13 It was reported to promote cell growth and vascular growth in Matrigel and to accelerate recovery from hindlimb ischaemia via activation of Akt-and endothelial nitric oxide synthase-related pathways.
14 Endothelium-specific VEGF-B transgenic mice displayed elevated vascular growth in an aortic explant assay. 14 However, VEGF-B deficient mice showed no gross abnormalities in the heart, and exhibited normal responses to VEGF-or fibroblast growth factor-(FGF)-induced angiogenesis. 15 Moreover, VEGF-B was found to be unnecessary for blood vessel growth in the mouse cornea pocket assay and rabbit hindlimb ischaemia model. 16 VEGF-B exerts a pro-survival role on endothelial cells, smooth muscle cells, and pericytes by regulating vascular pro-survival genes. 16 Cardiac-specific over-expression of VEGF-B altered lipid metabolism and induced myocardial hypertrophy 17 through the activation of cardiac VEGF receptor 1 (VEGFR-1). 18 Taken together, these findings indicate that VEGF-B plays a role in the regulation of endothelial cells and of cardiomyocytes. However, the means by which VEGF-B regulation of endothelial cells and of cardiomyocytes are linked has not been determined.
In the present study, we report the molecular mechanisms of transcriptional control of VEGF-B expression in vivo and in vitro. We found that increased RTEF-1 expression by endothelial cells up-regulated VEGF-B, which was able to stimulate hypertrophic genes in cardiomyocytes. These results suggest that an RTEF-1-driven increase in expression of VEGF-B plays an important role in communication between vascular endothelium and myocardium.
Methods

Animal models and transverse aortic constriction surgery
RTEF-1 transgenic mice were generated on the FVB background at the Beth Israel Deaconess Medical Center (BIDMC) Transgenic Core Facility using the VE-cadherin promoter to drive endothelium-specific expression of human RTEF-1. The investigation conforms to the Guide for the Care and Use of Laboratory Animals (NIH publication no. 1996) and was approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. Pressure overload was produced by transverse aortic constriction (TAC; see Supplementary material online 1) as described. 19 Echocardiography was performed at regular intervals.
Left ventricular diastolic dimension (LVDd) and left ventricular systolic dimension (LVDs) were measured. The percentage of LV fractional shorting (FS) was calculated as follows: (LVDd 2 LVDs)/LVDd × 100%.
Cell culture and hypoxia
The cell lines used included human dermal microvascular endothelial cells-1 (HMEC-1; Center for Disease Control and Prevention), rat myoblast cell line (H9C2) and human embryonic kidney cell line (HEK293). Mouse endothelial cells were isolated using PECAM-1 antibody (Pharmingen) and Dynabeads (Dynal) and confirmed by PECAM-1 immunostaining. Neonatal rat ventricular myocytes (NRVMs) were isolated from ventricular tissue of 1-day-old Sprague-Dawley rats (see Supplementary material online 2). Hypoxia was induced using a Modular Incubator Chamber (Billumps-Rothenberg) flushed with 5% CO 2 and 95% N 2 .
The concentration of oxygen (1 -3%) was determined before and after incubation by using an oxygen analyser (Vascular Technology). All cells were starved with serum-free medium for 12 h before normoxia, hypoxia or growth factor treatment.
Retroviral transduction and small interfering RNA transfection
The coding sequence of human RTEF-1 (Genbank ID: NM_003213.1) was subcloned into pBMN-GFP vector (Orbigen) from PXJ40/RTEF-1 construct (a gift from Dr Alexandre Stewart, University of Ottawa). HEK 293T cells were transfected with pBMN-GFP-RTEF-1 or pBMN-GFP, pMD-VSVG, pJK3, and pCMV-tat using polyethylenimine (PEI; Polysciences). The viruscontaining medium was transferred to HMEC-1 and selected with puromycin (250 ng/mL). Small interfering RNA (siRNA) encoding human RTEF-1 or VEGF-B (NM_003377.3; Genpharma Shanghai; Supplementary material online 3) was transfected using Lipofectamine 2000 (Invitrogen) and confirmed by western blotting. Small interfering RNA that is not targeted to any human genes was used as a negative control.
RNA and protein analyses
Total RNA was extracted from tissues or cultured cells. 
Promoter activity and chromatin immunoprecipitation
The VEGF-B reporter construct containing the 5 ′ flanking region (2851 to +156) of human VEGF-B (Genbank ID: NM_003377.3) was purchased from SwitchGear Genomics. HEK293 cells were transfected with VEGF-B reporter and RTEF-1 constructs using Lipofectamine 2000. The amount of control vector PJX40 was used for compensatory total volume of DNA. After 24 h transfection, luciferase activity was determined using the Dual-Luciferase assay system (Promega). Chromatin immunoprecipitation (ChIP) was performed with the ChIP-IT Express Kit (Active Motif) according to the manufacturer's instructions. The primer pairs 5 ′ -CCAGGTGCCCTCTCCTCCAG-3 ′ and 5 ′ -AAGG AAGCAAAGCGGGAACG-3 ′ for VEGF-B and 5 ′ -TGCACTGTGCG GCGAAGC-3 ′ and 5 ′ -TCGAGCCATAAAAGGCAA-3 ′ for actin as control were amplified. VEGF-B primers were designed to the putative MCAT element binding site for RTEF-1.
Immunofluorescence analysis
Heart samples were embedded in O.C.T. compound (Sakura Finetek USA Inc.) and frozen at 2808C. Tissue sections and fixed cultured neonatal cardiomyocytes were stained with antibodies against wheat germ agglutinin (Sigma), lectin (Sigma), a-actinin (Sigma) and 4 ′ 6-diamidino-2-phenylindole (DAPI) (Invitrogen) according to the manufacturers' instructions. The cross-sectional area of cardiomyocytes and vessel density were determined using ImageJ software.
Amino acid incorporation assay
Cardiomyocytes (H9C2, RNCM) were plated in a 24-well dish and subsequently starved for 24 h in DMEM lacking fetal calf serum.
3 H-Leucine (3 mCi/mL; Perkin Elmer) was then added to each well containing cells either in the presence or absence of 100 ng/mL VEGF-B, or 100 ng/mL VEGF-B + 10 mM U0126 treatment and cultured for an additional 20 h. Subsequently, cells were washed twice with 1 mL cold phosphatebuffered saline, followed by an incubation for 1 h at 48C in 1 mL cold 10% trichloracetic acid (TCA). After one wash with TCA solution and one wash with phosphate-buffered saline, proteins were solubilized with 0.2 mL 0.5 M NaOH for 1 h at room temperature and transferred to scintillation tubes containing 3 mL Ultima Gold XR scintillation liquid. The 3 H-leucine incorporation was determined using a LS6500 Beckman Coulter scintillation counter.
Statistical analysis
Results are expressed as the mean values + SEM. Multiple comparisons among three or more groups were carried out by one-way ANOVA and Fisher's exact test for post hoc analysis. A value of P , 0.05 was considered significant.
Results
Generation of endothelium-specific RTEF-1 transgenic mice
Transgenic mice with endothelium-specific expression of human RTEF-1 were generated using a mouse VE-Cadherin promoter. As expected, genotyping by PCR produced a 300 bp band for the transgenic gene ( Figure 1A) . Western blot was used to assess the specificity of endothelial expression of RTEF-1. Increased expression of RTEF-1 was found in hearts ( Figure 1B ) and isolated endothelial cells from VE-Cad/RTEF-1 mouse hearts in comparison with endogenous RTEF-1 expression ( Figure 1C ).
Exacerbation of cardiac hypertrophy in VE-Cad/RTEF-1 mice after pressure overload
To assess the effect of endothelium-specific increased expression of RTEF-1 on the heart, cardiac parameters of VE-Cad/RTEF-1 mice that underwent TAC surgery were examined. The VE-Cad/RTEF-1 mice showed an increased response to the pressure overload stimulus. Measurements made 8 weeks after TAC revealed that the ratio of heart weight to tibia length (HW/TL) was increased in VE-Cad/ RTEF-1 compared with wild-type (WT) mice (10.6 + 1.0 vs. 9.3 + 0.5 mg/mm; Figure 2A ). Enlarged cross-sectional areas of cardiomyocytes were found in VE-Cad/RTEF-1 compared with WT mice (293.6 + 4.7 vs. 242.8 + 5.6 mm 2 ; Figure 2B ). Echocardiography revealed a significant increase in wall thickness in VE-Cad/RTEF-1 mice compared with WT mice (0.88 + 0.03 vs. 0.80 + 0.01 mm; Figure 2C and D), and a significant decline of heart function in both VE-Cad/RTEF-1 and WT mice (42.5 + 2.0 vs. 44.6 + 2.3%) after TAC ( Figure 2E ). In addition, transcripts of hypertrophic gene markers, ANP and b-MHC, were significantly up-regulated in VE-Cad/RTEF-1 mice compared with WT mice after TAC ( Figure 2F ). These results indicated that endothelium-specific RTEF-1 transgenic mice developed more significant cardiac hypertrophy after a pathological stimulus resulting from TAC.
Elevation of VEGF-B in VE-Cad/RTEF-1 mice exacerbates cardiac hypertrophy
Our previous finding suggested that RTEF-1 is a pro-angiogenic transcription factor as a consequence of its VEGF-A promoter regulatory The data from three independent experiments performed in triplicate were analysed and normalized to 36b4 content (n ¼ 3). *P , 0.05 and **P , 0.01. activity. 7, 11 We therefore examined the expression of VEGFs in mouse hearts. As shown in Figure 3A , expression of both VEGF-A and VEGF-B was increased in the hearts of VE-Cad/RTEF-1 mice. However, compared with WT mice 8 weeks after TAC, VEGF-B was dramatically elevated in VE-Cad/RTEF-1 mice ( Figure 3A) . Furthermore, the elevation was detected as early as day 7 after TAC ( Figure 3B ), indicating that VEGF-B might participate in the development of cardiac hypertrophy in endothelium-specific RTEF-1 transgenic mice. Moreover, lectin staining of cardiac sections showed increased vessel density 8 weeks after TAC ( Figure 3C ), suggesting that angiogenesis is also involved in cardiac hypertrophy.
Induction of VEGF-B expression by RTEF-1 in hypoxic endothelial cells
In considering how endothelial expression of RTEF-1 stimulates cardiac signalling, the target genes of RTEF-1 were examined by a microarray analysis in endothelial cells with RTEF-1 siRNA (data not shown). Among the down-regulated genes, secreted proteins characterized by signal sequences without any transmembrane domains were determined using amino acid sequence screening with Signal IP and SOSUI software. 20 VEGF-B as a secreted protein was found to be significantly induced by RTEF-1 in endothelial cells.
Considering that there is a mismatch of capillaries and cardiac growth, leading to myocardial hypoxia during the development of cardiac hypertrophy, 21 secreted VEGF-B in hypoxia-conditioned medium was examined. VEGF-B was found to be significantly increased in HMEC-1/RTEF-1 compared with HMEC-1/pBMN (vector only for control), as well as in isolated endothelial cells from hearts of VE-Cad/RTEF-1 mice in both normoxia and hypoxia ( Figure 4A and B) . Increased VEGF-B secretion could also be detected in conditioned medium from HMEC-1/RTEF-1 exposed to normoxia or hypoxia for 12 h ( Figure 4A ). Meanwhile, VEGF-A and FGF2 but not tumour necrosis factor-a were found in the conditioned medium and could be induced by hypoxia, whereas the expression of FGF2 did not change in RTEF-1/HMEC cells ( Figure 4A ). Furthermore, knockdown of RTEF-1 by siRNA was associated with decreased expression of VEGF-B in endothelial cells in both normoxia and hypoxia ( Figure 4C ).
To determine whether RTEF-1 stimulates VEGF-B at a transcriptional level, the activity of a luciferase construct under the control of a VEGF-B promoter was measured. Co-transfection of VEGF-B/ luciferase with increasing amounts of RTEF-1 cDNA produced a dosedependent increase in luciferase activity ( Figure 4D) . Moreover, RTEF-1 stimulated VEGF-B promoter activity in both normoxic and hypoxic conditions, although significantly greater stimulation occurred in hypoxic conditions ( Figure 4E ). Sequence analysis indicated that there are MCAT-like elements and Sp1 binding sequences located in the promoter region of VEGF-B. To confirm the interaction between RTEF-1 and VEGF-B, ChIP assay revealed a direct interaction between RTEF-1 and the VEGF-B promoter via binding to MCAT-like element ( Figure 4F) , and Sp1 sequences were not detected to have any binding activity (data not shown). These results imply that RTEF-1 induces VEGF-B expression and secretion in endothelial cells, and this induction was enhanced in hypoxic conditions.
Pro-hypertrophic role of RTEF-1-induced VEGF-B on cardiomyocytes
To further investigate the effect on cardiomyocytes of RTEF-1 expressed by endothelial cells, H9C2 were incubated with conditioned medium from hypoxia-treated HMEC-1/RTEF-1 or HMEC-1/pBMN. qPCR showed that mRNA levels of the hypertrophic gene markers ANP, BNP, a-MHC, and b-MHC were significantly increased after incubation with conditioned medium from HMEC-1/ RTEF-1 compared with incubation with conditioned medium from HMEC-1 control cells ( Figure 5A ). Similar results were found in H9C2 cells after incubation with recombinant human VEGF-B 167 (rhVEGF-B 167 ; Figure 5B ). The effects of hypoxia-conditioned medium from HMEC-1/RTEF-1 and VEGF-B on protein synthesis were analysed by measurement of 3 H-Leucine incorporation into H9C2 as shown in Figure 5C . To further confirm that VEGF-B is a key molecule in RTEF-1-driven endothelial cell communication with cardiomyocytes, we used two siRNAs targeted at VEGF-B to knock down VEGF-B expression in HMEC-1/RTEF-1 ( Figure 5D ). VEGF-B siRNA significantly inhibited the pro-hypertrophic effect of the conditioned medium ( Figure 5D ). To confirm these results, experiments were repeated using isolated endothelial cells from hearts of VE-Cad/RTEF-1 mice and neonatal rat ventricular myocytes (NRVMs). As observed for H9C2 cells, the expression of ANP, BNP, and b-MHC was induced in NRVMs after incubation with conditioned medium from hypoxia-treated endothelial cells of VE-Cad/ RTEF-1 but not after incubation with conditioned medium from WT mice ( Figure 5E ). Moreover, NRVMs incubated with rhVEGF-B 167 exhibited enlarged cardiomyocytes ( Figure 5F ). These data suggested that increased RTEF-1 in endothelial cells stimulated production and secretion of VEGF-B, thereby triggering expression of hypertrophic genes in cardiomyocytes.
Induction of VEGF-B in cardiac hypertrophy via phosphorylation of ERK1/2
To examine the downstream signalling pathway of VEGF-B, NRVMs were treated with rhVEGF-B 167 at different doses for various time periods. ERK1/2, but not P38 or JNK, was significantly phosphorylated by VEGF-B ( Figure 6A ). The rhVEGF-B 167 -induced phosphorylation of ERK1/2 could be abolished by treatment with the ERK1/2 specific blocker, U0126 ( Figure 6B ). Phosphorylation of ERK1/2 was also confirmed in heart samples from VE-Cad/RTEF-1 mice after TAC ( Figure 6C) . Furthermore, VEGF-B-induced expression of hypertrophic gene markers in H9C2 could be partly blocked by U0126 ( Figure 6D ). In addition, following rhVEGF-B 167 treatment an increase in protein synthesis was observed in H9C2 and RNVM by the amino acid incorporation assay. Furthermore, ERK1/2 inhibitor significantly attenuated VEGF-B-induced protein synthesis in cardiomyocytes ( Figure 6E ).
Discussion
It is known that RTEF-1 plays a key role in the regulation of transcription in muscular cells. 8 However, the target genes of RTEF-1 in nonmuscle cells have not been fully investigated. Endothelium-specific RTEF-1 transgenic mice may provide an efficient model to dissect the function of RTEF-1 in endothelium. In this study, we demonstrated that the mechanism of exacerbated cardiac hypertrophy in endothelium-specific RTEF-1 transgenic mice is correlated to RTEF-1 transcriptional up-regulation of VEGF-B by the following lines of evidences. First, VE-Cad/RTEF-1 mice had elevated VEGF-B expression and developed more significant cardiac hypertrophy after the pressure overload stimulus. Secondly, RTEF-1 stimulated VEGF-B promoter activities via binding to MCAT element and regulated VEGF-B expression in endothelial cells. Thirdly, conditioned media from endothelial cells over-expressing RTEF-1 acted as a cardiac pro-hypertrophic stimulator, which could be blocked by VEGF-B knock-down. Finally, rhVEGF-B 167 could induce a similar prohypertrophic effect on cardiomyocytes via phosphorylation of the ERK1/2 signalling pathway. Capillary endothelial cells lie in close proximity to cardiomyocytes in the heart. The communication between these two cell types involves reciprocal gene regulation, signal transduction and energy supply. 22 Cardiomyocytes induce endothelial expression of endogenous von Willebrand factor as well as von Willebrand factor promoter activity in both in vitro and in vivo conditions. 23 Hypoxic cardiomyocytes induce endothelial expression of cyclo-oxygenase-2 in a VEGFdependent pathway. 24 In contrast, endothelial cells within the heart may release a number of substances, including endothelin 25 and angiotensin-converting enzyme, 26 to modulate myocardial function.
RTEF-1, as a hypoxia-induced transcriptional factor, 7,11 may be involved in this communication by targeting several genes in which some have signalling domains. Hypoxia occurs during development of hypertrophy in pressure overload. 27 The endothelium-driven RTEF-1 inducing VEGF-B to target cardiomyocytes demonstrates that transcription factors can lead to a cross-talk between two cell types to impact cardiac functions. The changes in endotheliummyocyte cross-talk induced by RTEF-1 may contribute to and/or arise from cardiac pathologies. RTEF-1 has been reported to regulate gene expression transcriptionally by binding to the MCAT elements and Sp1 binding sequences of promoters. 7, 8, 11 Sequence analyses have indicated that the VEGF-B promoter region contains Sp1 binding sequences and MCAT elements, either of which could be the potential binding site for RTEF-1. The evidence presented in this report indicates that RTEF-1 regulates VEGF-B in endothelial cells through a direct interaction with the MCAT-like elements on the VEGF-B promoter. It has been reported that the VEGF-B transcript was stable when cultured fibroblast cells were treated with hypoxia, serum, growth factors or hormones. 28 It is possible that VEGF-B is regulated by different mechanisms in various cell types. Cell-specific co-factors necessary for RTEF-1-mediated expression might be available in endothelial cells but not in other types of cells. Expression of VEGF-B was significantly elevated in hearts of VE-CAD/RTEF-1 mice after TAC, implying that VEGF-B might play an important role in cross-talk between RTEF-1-expressing endothelial cells and cardiomyocytes. Unlike VEGF-A, VEGF-B has a very limited angiogenic effect. 29 In contrast, VEGF-B was reported to be anti-apoptotic in neurons, 30 smooth muscle cells, pericytes, RTEF-1 regulates cardiac hypertrophy via VEGF-B and endothelial cells 16 by regulating pro-survival genes via both neuropilin-1 (NP-1) and VEGFR-1. Cardiomyocytes incubated with conditioned medium from RTEF-1-over-expressing endothelial cells or incubated with rhVEGF-B 167 exhibited significant increases in expression of hypertrophic gene markers and protein synthesis through ERK mitogen-activated protein kinase activation. Furthermore, induction of these markers was blocked by VEGF-B knockdown with siRNA. These findings are consistent with recent observations that cardiac-specific VEGF-B transgenic mice exhibit significant cardiac hypertrophy, 17 as well as with the observation that VEGF-B activates VEGFR-1 to elicit a particular hypertrophic response in cultured cardiomyocytes and in infarcted hearts. 18 It was also found that ERK mitogen-activated protein kinase signalling plays a key role in cardiac hypertrophy. 31 However, whether RTEF-1-induced VEGF-B in this study exerts an anti-apoptotic effect requires further investigation. RTEF-1 is able to up-regulate the VEGF-A gene in hypoxic conditions in bovine aortic endothelial cells. 7 In this study, VEGF-A was also found to be involved in the development of cardiac hypertrophy, as evidenced by elevated VEGF-A expression and increased vessel H-Leucine incorporation assay indicates the level of protein synthesis in H9C2 and RNCM cultures after incubation of VEGF-B with and without ERK1/2 inhibitor U0216. Bars represent radioactivity of incorporated density in the heart after pressure overload in vivo. It has been reported that cardiac growth and angiogenesis is co-ordinated by angiogenic growth factors in response to hypertrophic stimuli. 3 An imbalance between angiogenesis and cardiac growth can lead to heart failure, 3 which is consistent with the clinical findings that dilated cardiomyopathy is associated with an irregular capillary pattern and a reduction in overall capillary density. 5, 32 We found that transcriptional control of VEGF-B by RTEF-1 in endothelial cells plays a direct role in regulation of hypertrophic gene expression in cardiomyocytes. This regulation of VEGF-B by RTEF-1 might be independent of angiogenesis, providing evidence of communication between the two cell types in the heart.
Conclusion
We demonstrated that transcriptional regulation by RTEF-1 in endothelial cells is involved in the development of cardiomyocyte hypertrophy. We identified VEGF-B as a target gene of RTEF-1 that appears to play an important role as a bridge between endothelial cells and cardiomyocytes during development of cardiac hypertrophy induced by pressure overload. These results suggest that transcriptional control of the VEGF pathway in the communication between endothelial cells and cardiomyocytes will lead to a better understanding of the precise mechanisms of angiogenesis and cardiac hypertrophy, and ultimately the development of new therapeutic strategies.
